Johnson & Johnson has proposed a $5.5 billion settlement to resolve tens of thousands of ovarian cancer talc lawsuits. The offer targets roughly 76,000 claims in federal and state courts and would require approval from a majority of claimants before it can move forward. The settlement aims to convert an open-ended legal liability into a structured payment schedule, potentially reducing uncertainty around future cash outflows. The proposal follows earlier failed attempts to ringfence liabilities through bankruptcy and does not eliminate the possibility of future cases. Johnson & Johnson shares have returned 28.1% year to date and closed at $265.53.
Johnson & JohnsonProposed $5.5B settlement aims to resolve talc lawsuits, reducing legal uncertainty.